Research Topics
| Colin BaigentSummaryAffiliation: University of Oxford Country: UK Publications
| Collaborators
|
Detail Information
Publications
Which cardiovascular risk factors matter in chronic kidney disease?Colin Baigent
Clinical Trial Service Unit and Epidemiological Studies Unit CTSU, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK
Nephrol Dial Transplant 22:9-11. 2007- Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trialsColin Baigent
Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, UK
Semin Dial 20:498-503. 2007.... - Ensuring trial validity by data quality assurance and diversification of monitoring methodsColin Baigent
Clinical Trial Service Unit and Epidemiological Studies Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF
Clin Trials 5:49-55. 2008.... - Aspirin for everyone older than 50? AgainstColin Baigent
Clinical Trial Service Unit and Epidemiological Studies Unit, Radcliffe Infirmary, Oxford OX2 6HE
BMJ 330:1442-3. 2005 - First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney diseaseColin Baigent
Clinical Trial Service Unit, Oxford University, Oxford, UK
Am J Kidney Dis 45:473-84. 2005..Patients with chronic kidney disease are at increased risk for cardiovascular disease, but the efficacy and safety of simvastatin and aspirin are unknown in this patient group... - Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trialsColin Baigent
Clinical Trial Service Unit and Epidemiological Studies Unit, Radcliffe Infirmary, Woodstock Road, Oxford, OX2 6HE, UK
Curr Opin Nephrol Hypertens 13:601-5. 2004..This review outlines the limited information currently available on the effects of statins among patients with chronic kidney disease, and summarizes the ongoing randomized trials designed to address this question... - Randomization is essential for progress in transplant medicineColin Baigent
Clinical Trial Service Unit and Epidemiological Studies Unit CTSU, University of Oxford, Oxford, United Kingdom
Transplantation 86:26-7. 2008..Even after adjustment, nonrandomized studies may have large biases, so are not a suitable alternative to large randomized trials... - Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsColin Baigent
CTSU, Oxford University, Oxford, UK
Lancet 373:1849-60. 2009..Low-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in primary prevention... - The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKDMartin Landray
Clinical Trial Service Unit, University of Oxford, Churchill Hospital, Oxford, UK
Am J Kidney Dis 47:385-95. 2006..In preparation for such a trial, we assessed the biochemical efficacy, safety, and tolerability of adding ezetimibe, 10 mg/d, to simvastatin, 20 mg/d, as initial therapy for such patients... - Analyses of cancer data from three ezetimibe trialsRichard Peto
Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford University, Oxford, United Kingdom
N Engl J Med 359:1357-66. 2008..gov number, NCT00092677) has raised the hypothesis that adding ezetimibe to statin therapy for larger LDL cholesterol reductions might increase the incidence of cancer... - The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialColin Baigent
Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK
Lancet 377:2181-92. 2011..The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients... - Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort studyMartin J Landray
Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK
Am J Kidney Dis 56:1082-94. 2010..Validated prediction scores are required to assess the risks of end-stage renal disease (ESRD) and death in individuals with chronic kidney disease (CKD)... - Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsPatricia M Kearney
Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford OX3 7LF
BMJ 332:1302-8. 2006..To assess the effects of selective cyclo-oxygenase-2 (COX 2) inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of vascular events... - Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysisMarion Mafham
Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom
PLoS ONE 6:e25920. 2011..We used a novel method to summarise the published results... - Statins: are any questions unanswered?Patricia M Kearney
Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, UK
Curr Opin Lipidol 17:418-25. 2006..To summarize recent and ongoing randomized trials of statin therapy for the prevention of major vascular events... - A practical method of measuring glomerular filtration rate by iohexol clearance using dried capillary blood spotsMarion M Mafham
Renal Studies Group, Clinical Trial Service Unit, Old Road Campus, Oxford, UK
Nephron Clin Pract 106:c104-12. 2007..Exogenous tracer-based methods of measuring glomerular filtration rate (GFR) are difficult to perform, whilst creatinine-based estimation formulae are inaccurate... - Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) studyMartin J Landray
Clinical Trial Service Unit, University of Oxford, Oxford, UK
Am J Kidney Dis 43:244-53. 2004..Studies in the general population suggest that low-grade inflammation, endothelial dysfunction, and platelet activation are associated with an increased risk of cardiovascular events... - Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisalColin Baigent
Clinical Trial Service Unit, Radcliffe Infirmary, Oxford, UK
Arthritis Rheum 48:12-20. 2003 - Cholesterol and the risk of renal dysfunction in apparently healthy menElke S Schaeffner
Divisions of Preventive Medicine, and Aging, and Cardiovascular Disease, and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
J Am Soc Nephrol 14:2084-91. 2003..5 mg/dl... - Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Carlo Patrono
Catholic University School of Medicine, Largo F Vito 1, Rome, Italy
Chest 133:199S-233S. 2008.... - Low-dose aspirin for the prevention of atherothrombosisCarlo Patrono
Department of Pharmacology, University of Rome La Sapienza, Rome, Italy
N Engl J Med 353:2373-83. 2005 - Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesisCharles H Hennekens
Center of Excellence, Florida Atlantic University, USA
Nat Clin Pract Cardiovasc Med 3:4-5. 2006 - Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) studyDaniel Zehnder
Department of Nephrology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK
Nephron Clin Pract 107:c109-16. 2007..However, it is unclear at what stage of chronic kidney disease (CKD) these abnormalities develop... - Article makes simple errors and could cause unnecessary deathsColin Baigent
BMJ 324:167. 2002 - [Expert consensus document on the use of antiplatelet agents]Carlo Patrono
Rev Esp Cardiol 57:963-80. 2004 - Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiologyCarlo Patrono
ESC Task Force on Antiplatelets, University of Rome La Sapienza, , Via di Grottarossa, 1035, 00189 Roma, Italy
Eur Heart J 25:166-81. 2004 - B vitamins for the prevention of vascular disease: insufficient evidence to justify treatmentColin Baigent
JAMA 298:1212-4. 2007 - Anticoagulants in heart disease: current status and perspectivesRaffaele De Caterina
Institute of Cardiology, G. d'Annunzio University - Chieti, Ospedale S. Camillo de Lellis, Chieti, Italy
Eur Heart J 28:880-913. 2007